Protagonist Therapeutics, Inc. or Mesoblast Limited: Who Invests More in Innovation?

Biotech Giants: A Decade of R&D Investment Shifts

__timestampMesoblast LimitedProtagonist Therapeutics, Inc.
Wednesday, January 1, 2014553050007459000
Thursday, January 1, 20157759300011831000
Friday, January 1, 20165001300025705000
Sunday, January 1, 20175891400046181000
Monday, January 1, 20186592700059497000
Tuesday, January 1, 20195981500065003000
Wednesday, January 1, 20205618800074506000
Friday, January 1, 202153012000126006000
Saturday, January 1, 202232815000126215000
Sunday, January 1, 202327189000120161000
Monday, January 1, 202425353000
Loading chart...

Data in motion

Innovation Investment: A Tale of Two Biotech Companies

In the competitive world of biotechnology, innovation is the lifeblood of success. Protagonist Therapeutics, Inc. and Mesoblast Limited are two companies that have been at the forefront of this race. Over the past decade, Protagonist Therapeutics has consistently increased its investment in research and development (R&D), with a remarkable 1,500% growth from 2014 to 2023. In contrast, Mesoblast Limited's R&D spending has seen a decline of approximately 54% over the same period.

A Decade of Change

In 2014, Mesoblast Limited led the charge with R&D expenses nearly seven times that of Protagonist Therapeutics. However, by 2023, Protagonist Therapeutics had not only closed the gap but surpassed Mesoblast, investing over four times more in innovation. This shift highlights Protagonist's commitment to advancing its research capabilities, while Mesoblast's reduced spending may indicate a strategic pivot or financial constraints.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025